MedTrace Logo

The Lymphoma and Leukemia Society Amended COVID-19 Registry

NCT04794387 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-03-02

No results posted yet for this study

Summary

The LLS COVID-19 Registry is being amended to invite people who participated in the LLS COVID-19 Registry and did not develop antibodies after receiving a complete COVID-19 vaccination, as well as people with blood cancer who did not participate in the initial LLS COVID-19 Registry and also did not develop antibodies after receiving a complete COVID-19 vaccination, to participate in this amended LLS COVID-19 Registry.

Conditions

  • Covid19

Interventions

BIOLOGICAL

Amended LLS COVID-19 Registry

Do people with blood cancer who did not develop antibodies after a complete COVID-19 vaccination, develop antoibodies after a COVID-19 booster?

Sponsors & Collaborators

  • Lymphoma and Leukemia Society

    lead OTHER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-27
Primary Completion
2022-12-13
Completion
2022-12-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04794387 on ClinicalTrials.gov